ERBB2 and breast carcinoma: The last clinical trial for HER2+ breast cancer patients that is open and recruiting is a phase 1/2 study (NCT04650451) that investigates the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, called BPX-603, administered with rimiducid, a lipid-permeable tacrolimus analogue, and a protein dimerizer, to subjects with previously treated, locally advanced, or metastatic solid tumors that are HER2+ [309].